Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing
Open Access
- 20 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 18 (1), 1-13
- https://doi.org/10.1186/s12885-018-4639-4
Abstract
Colorectal cancer (CRC) patients with metastatic disease can become cured if neoadjuvant treatment can enable a resection. The search for predictive biomarkers is often performed on primary tumours tissue. In order to assess the effectiveness of tailored treatment in regard to the primary tumour the differences in the genomic profile needs to be clarified. Fresh-frozen tissue from primary tumours, synchronous liver metastases and adjacent normal liver was collected from 21 patients and analysed by whole-exome sequencing on the Illumina HiSeq 2500 platform. Gene variants designated as ‘damaging’ or ‘potentially damaging’ by Ingenuity software were used for the subsequent comparative analysis. BAM files were used as the input for the analysis of CNAs using NEXUS software. Shared mutations between the primary tumours and the synchronous liver metastases varied from 50 to 96%. Mutations in APC, KRAS, NRAS, TP53 or BRAF were concordant between the primary tumours and the metastases. Among the private mutations were well-known driver genes such as PIK3CA and SMAD4. The number of mutations was significantly higher in patients with right- compared to left-sided tumours (102 vs. 66, p = 0.004). Furthermore, right- compared to left-sided tumours had a significantly higher frequency of private mutations (p = 0.023). Similarly, CNAs differed between the primary tumours and the metastases. The difference was mostly comprised of numerical and segmental aberrations. However, novel CNAs were rarely observed in specific CRC-relevant genes. The examined primary colorectal tumours and synchronous liver metastases had multiple private mutations, indicating a high degree of inter-tumour heterogeneity in the individual patient. Moreover, the acquirement of novel CNAs from primary tumours to metastases substantiates the need for genomic profiling of metastases in order to tailor metastatic CRC therapies. As for the mutational status of the KRAS, NRAS and BRAF genes, no discordance was observed between the primary tumours and the metastases.Keywords
Funding Information
- The Danish Council for Strategic Research (10-092308)
- King Chr. X’s Fund
- ER Frederiksen Fund
- Thora & Viggo Grove Fund
- Messerschmidt Family Fund
- Niels Hansen Fund
- Harboe Foundation
- Lykfeldt Fund
- Spar Nord Fund
- Axel Muusfeldt Fund
- Einar Willumsen Fund
- Else & Mogens Wedell-Wedellsborg Fund
- Arvid Nilsson Fund.
- Misse & Valdemar Risoms Fund
This publication has 42 references indexed in Scilit:
- Comprehensive identification of mutational cancer driver genes across 12 tumor typesScientific Reports, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patientsBritish Journal of Cancer, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- A diagnostic paradigm for resectable liver lesions: to biopsy or not to biopsy?HPB, 2009
- Different molecular patterns in glioblastoma multiforme subtypes upon recurrenceJournal of Neuro-Oncology, 2009
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- APC mutations occur early during colorectal tumorigenesisNature, 1992